
Opinion|Videos|January 3, 2025
Exploring Updates on AMPLIFY at ASH 2024
Experts examine both overall survival outcomes and independent review committee–assessed progression-free survival data from the AMPLIFY trial.
Advertisement
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
FDA Accepts BLA for Ivonescimab in Pretreated EGFR-Mutated NSCLC
2
NCCN Updates Breast Cancer Guidelines: Sacituzumab Govitecan for 1L TNBC
3
Ropeginterferon Alfa Gains NCCN Backing in Essential Thrombycythemia
4
Multiomic Real-World Data Predict Outcomes in Metastatic Breast Cancer
5




















